BIVI

BioVie Inc. [BIVI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BIVI Stock Summary

Top 10 Correlated ETFs

BIVI


Top 10 Correlated Stocks

BIVI


In the News

10:55 28 Mar 2024 BIVI

Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now

BioVie Inc. (BIVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

08:56 28 Mar 2024 BIVI

BioVie to kick off Phase 2b trial for lead asset in Parkinson's disease in late-summer

BioVie Inc (NASDAQ:BIVI) told investors it has secured sufficient funds through a recently completed financing to progress its near-term clinical priority, developing its lead asset NE3107 for Parkinson's disease. It increased its cash balance by approximately $18.8 million after closing an equity financing round last week for gross proceeds of $21 million.

10:57 28 Mar 2024 BIVI

Why Is BioVie (BIVI) Stock Up 100% Today?

BioVie (NASDAQ: BIVI ) stock is rocketing higher on Friday announed positive data from two clinical trials of NE3107. NE3107 is BioVie's inhibitor of inflammatory activation of ERK and NFkB.

09:49 28 Mar 2024 BIVI

BioVie shares surge on lead asset NE3107's potential to improve Parkinson's Disease symptoms

BioVie Inc (NASDAQ:BIVI) shares surged 130% in early trade on Friday after the company revealed that its lead asset NE3107 has demonstrated the potential to improve motor and non-motor symptoms in patients with Parkinson's disease in a mid-stage clinical trial.  The company said data from its Phase 2a trial showed Parkinson's Disease patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control, while patients in the placebo arm worsened.

11:18 28 Mar 2024 BIVI

BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

12:01 28 Mar 2024 BIVI

BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data

BioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company.

11:38 28 Mar 2024 BIVI

Why Is BioVie (BIVI) Stock Down 63% Today?

BioVie (NASDAQ: BIVI ) stock is falling on Wednesday after the company released data from a Phase 3 clinical trial of its Alzheimer's Disease treatment candidate NE3107. Unfortunately for investors in BIVI stock, that study failed to meet its primary endpoint of statistical significance.

08:48 28 Mar 2024 BIVI

BioVie reports efficacy data from NE3107 Phase 3 trial for Alzheimer's Disease

BioVie Inc (NASDAQ:BIVI), the clinical-stage company specializing in drug therapies for neurological disorders, revealed new results from the Phase 3 trial of NE3107 in patients with mild to moderate Alzheimer's Disease (AD). The trial, initiated during the COVID-19 pandemic, enrolled 439 patients across 39 sites.

08:12 28 Mar 2024 BIVI

BioVie: Cautiously Optimistic Ahead Of Phase 3 Alzheimer's Data Unblinding

Blinded Phase 3 data of NE3107 in Alzheimer's appear to indicate robust cognitive and biomarker efficacy. Market is significantly undervaluing the probability of a successful data unblinding expected shortly after Thanksgiving. Potential to be the first neurodegenerative biotech to show significant improvement in cognition Alzheimer's disease with suspected disease modification.

09:14 28 Mar 2024 BIVI

BioVie presents positive safety data from Phase 2 liver disease trial

BioVie Inc (NASDAQ:BIVI) has presented data from its Phase 2b trial evaluating the efficacy and safety of its drug candidate BIV201 for liver disease at The American Association for the Study of Liver Diseases – The Liver Meeting in Boston, Massachusetts. The company said the trial showed that BIV201 in combination with the standard of care in patients with refractory ascites due to cirrhosis was well tolerated with no major difference in treatment-emergent adverse events when compared to the standard of care alone.

BIVI Financial details

Company Rating
Neutral
Market Cap
31.61M
Income
-43.45M
Revenue
0
Book val./share
0.2
Cash/share
0.53
Dividend
-
Dividend %
-
Employees
18
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
-0.87
Forward P/E
-0.42
PEG
-0.3
P/S
-
P/B
6.23
P/C
1
P/FCF
-1.12
Quick Ratio
1.61
Current Ratio
1.72
Debt / Equity
1.37
LT Debt / Equity
0
-
-
EPS (TTM)
-1.19
EPS next Y
-1.25
EPS next Q
-0.29
EPS this Y
68.48%
EPS next Y
5.04%
EPS next 5Y
-463.87%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-24.14%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-75%
Inst Own
0%
Inst Trans
0%
ROA
-227%
ROE
-305%
ROC
-4.47%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
54.92M
Shs Float
21.71M
-
-
-
-
Target Price
-
52W Range
0.5428-8.97
52W High
-
52W Low
-
RSI
36
Rel Volume
0.29
Avg Volume
2.48M
Volume
730.64K
Perf Week
-13.97%
Perf Month
-55.07%
Perf Quarter
-86.41%
Perf Half Y
-83.69%
-
-
-
-
Beta
1.335
-
-
Volatility
0.02%, 0.33%
Prev Close
-0.64%
Price
0.5302
Change
-2.72%

BIVI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-06-30

Metric History 2019-06-302020-06-302021-06-302022-06-30 2023-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.94-4.35-10.55-0.92-1.55
Operating cash flow per share
-0.99-0.33-0.84-0.77-1.24
Free cash flow per share
-0.99-0.33-0.84-0.77-1.24
Cash per share
0.130.010.360.761.04
Book value per share
0.84-4.360.410.150.47
Tangible book value per share
0.09-4.70.290.10.44
Share holders equity per share
0.84-4.360.410.150.47
Interest debt per share
01.150.050.590.58
Market cap
30.16M69.01M210.23M35.76M140M
Enterprise value
29.82M69.89M205.72M29.38M134.96M
P/E ratio
-12.6-3.22-1.61-1.57-2.79
Price to sales ratio
00000
POCF ratio
-12.06-42.39-20.11-1.88-3.48
PFCF ratio
-12.06-42.39-20.11-1.88-3.48
P/B Ratio
14.15-3.2141.639.749.13
PTB ratio
14.15-3.2141.639.749.13
EV to sales
00000
Enterprise value over EBITDA
-13.16-28.37-1.49-1.09-3.05
EV to operating cash flow
-11.92-42.92-19.68-1.55-3.35
EV to free cash flow
-11.92-42.92-19.68-1.55-3.35
Earnings yield
-0.08-0.31-0.62-0.64-0.36
Free cash flow yield
-0.08-0.02-0.05-0.53-0.29
Debt to equity
0-0.0403.340.94
Debt to assets
00.4400.610.41
Net debt to EBITDA
0.15-0.350.030.240.11
Current ratio
1.520.024.624.52.35
Interest coverage
-9.14K-0.56-246.77-12.6-10.48
Income quality
1.020.10.080.730.8
Dividend Yield
00.25000
Payout ratio
-0.02-0.8000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.740.80.240.060.03
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
4.2220.669.831.764.05
ROIC
-1.150.17-27.45-1.48-1.64
Return on tangible assets
-3.55-51.94-28.4-1.21-1.47
Graham Net
-0.04-4.780.280.090.44
Working capital
230.59K-23.11M3.61M14.61M19.55M
Tangible asset value
230.59K-23.17M3.61M2.46M14.36M
Net current asset value
230.59K-23.17M3.61M2.34M14.28M
Invested capital
0-0.0403.340.94
Average receivables
00000
Average payables
663.84K851.34K1.13M499.41K2.96K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
705.692K1.59K3.764.76
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.520.180.2397.1976.76
Inventory turnover
00000
ROE
-1.121-25.9-6.21-3.28
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q2

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.61-0.43-0.25-0.29-0.22
Operating cash flow per share
-0.26-0.33-0.31-0.33-0.15
Free cash flow per share
-0.26-0.33-0.31-0.33-0.15
Cash per share
1.471.240.940.580.53
Book value per share
0.840.610.420.210.2
Tangible book value per share
0.80.590.40.180.17
Share holders equity per share
0.840.610.420.210.2
Interest debt per share
0.460.420.430.360.29
Market cap
242.18M285.43M156.37M125.29M48.1M
Enterprise value
209.8M268.05M151.33M116.46M38.13M
P/E ratio
-3.2-4.69-4.29-2.92-1.43
Price to sales ratio
00000
POCF ratio
-30.24-24.32-13.85-10.29-8.14
PFCF ratio
-30.24-24.32-13.85-10.29-8.14
P/B Ratio
9.2913.1410.1916.66.42
PTB ratio
9.2913.1410.1916.66.42
EV to sales
00000
Enterprise value over EBITDA
-18.49-19.8-14.19-11.25-4.48
EV to operating cash flow
-26.2-22.84-13.41-9.56-6.45
EV to free cash flow
-26.2-22.84-13.41-9.56-6.45
Earnings yield
-0.08-0.05-0.06-0.09-0.17
Free cash flow yield
-0.03-0.04-0.07-0.1-0.12
Debt to equity
0.510.640.941.641.37
Debt to assets
0.280.310.410.520.48
Net debt to EBITDA
2.851.280.470.851.17
Current ratio
5.92.752.351.721.47
Interest coverage
-10.91-12.72-9.91-10.83-10.7
Income quality
0.510.781.241.140.7
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.020.020.030.040.04
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
3.382.441.551.160.99
ROIC
-0.35-0.39-0.41-0.59-0.54
Return on tangible assets
-0.41-0.34-0.27-0.47-0.41
Graham Net
0.790.580.390.140.16
Working capital
38.19M28.04M19.55M9.55M6.58M
Tangible asset value
24.97M20.68M14.36M6.62M6.62M
Net current asset value
24.87M20.58M14.28M6.55M6.56M
Invested capital
0.510.640.941.641.37
Average receivables
00000
Average payables
1.62M1.63M4.16K3.1K1.36K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
4.39K6.524.663.630
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.0213.8119.324.820
Inventory turnover
00000
ROE
-0.73-0.7-0.59-1.42-1.12
Capex per share
00000

BIVI Frequently Asked Questions

What is BioVie Inc. stock symbol ?

BioVie Inc. is a US stock , located in Carson city of Nv and trading under the symbol BIVI

What is BioVie Inc. stock quote today ?

BioVie Inc. stock price is $0.5302 today.

Is BioVie Inc. stock public?

Yes, BioVie Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap